Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib and Envafolimab in Advanced Soft Tissue Sarcoma
NCT05722977Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Feb 2023
- Primary completion
- Feb 2026
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
01
Overview
A Phase 2 trial of surufatinib, envafolimab in soft tissue sarcoma (STS), sponsored by Peking Union Medical College Hospital. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
surufatinibenvafolimab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05722977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05722977.